Search

Displaying results 2131 - 2140 of 6831 in total
  1. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  2. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Urea C-13

    go.drugbank.com/drugs/DB09510
    ApprovedInvestigational

    To detect H. pylori, urea labeled with 13C is swallowed by the patient. … The UBT is indicated to confirm H. pylori infection and to monitor post-treatment for its eradication. Radiolabelled urea is available in two forms as 13C and 14C.

  4. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. … [A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]

  5. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.

  6. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. … [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter

  7. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and … Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019.

  8. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.

  9. Drug

    Azilsartan medoxomil

    go.drugbank.com/drugs/DB08822
    ApprovedInvestigational

    Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. … [L32918] Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease.

  10. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … [L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that